View ValuationExagen 将来の成長Future 基準チェック /06Exagenは、27.6%と9.7%でそれぞれ年率27.6%で利益と収益が成長すると予測される一方、EPSはgrowで29.7%年率。主要情報27.6%収益成長率29.71%EPS成長率Biotechs 収益成長25.2%収益成長率9.7%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日12 May 2026今後の成長に関する最新情報分析記事 • May 14Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesExagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.分析記事 • Nov 07Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.すべての更新を表示Recent updates分析記事 • May 14Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesExagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United Statesお知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026ナラティブの更新 • Apr 24XGN: Volume Strength And 2026 Guidance Should Support Future Share GainsNarrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.ナラティブの更新 • Apr 10XGN: Shares Should Rise As Volumes Offset Transitory Pricing HeadwindsAnalysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.ナラティブの更新 • Mar 26XGN: Shares Should Rise As Volumes Support Long Term Margin RecoveryAnalysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.ナラティブの更新 • Mar 12XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing HeadwindsThe analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026ナラティブの更新 • Feb 11XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish OutlookNarrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.ナラティブの更新 • Jan 27XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen OutlookAnalysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.分析記事 • Jan 14Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...ナラティブの更新 • Jan 12XGN: Shares Will Rise As 2025 Guidance Supports Profitability MilestoneThe updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.ナラティブの更新 • Dec 21XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability ProspectsAnalysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.分析記事 • Dec 18Is Exagen (NASDAQ:XGN) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...ナラティブの更新 • Dec 07XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside PotentialAnalysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.ナラティブの更新 • Nov 22XGN: Shares Will Gain As Buy Ratings Signal 50% Upside PotentialAnalysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.分析記事 • Nov 18The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Nov 07Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...ナラティブの更新 • Nov 06XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside PotentialAnalysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.ナラティブの更新 • Oct 23Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic PortfolioAnalysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.お知らせ • Oct 22Exagen Inc. to Report Q3, 2025 Results on Nov 04, 2025Exagen Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025Seeking Alpha • Sep 13Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For NowSummary Exagen Inc. has rebounded to 52-week highs, driven by record Q2 revenue, higher ASP, and a strengthened balance sheet. XGN's pipeline, including PAD4 and lupus nephritis diagnostics, presents significant long-term growth opportunities but faces regulatory and reimbursement risks. Recent payer wins and executive appointments enhance commercial prospects, but collections risk and delayed insurance payments threaten near-term revenue stability. Given execution risks and valuation premium, I rate XGN as HOLD, awaiting clearer visibility on collections, payer wins, and PAD4 approval. Read the full article on Seeking Alpha分析記事 • Aug 05Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift TooNasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...分析記事 • Aug 01Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent ResultsIt's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...お知らせ • Jul 29Exagen Inc. Provides Earnings Guidance for the Full Year 2025Exagen Inc. provided earnings guidance for the full year 2025. For the year, company expects 2025 full-year revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to hit positive adjusted EBITDA in the fourth quarter.お知らせ • Jul 18Exagen Inc. Appoints Charles S. McKhann as A Class III Director and to the Compensation Committee and Nominating Committee, Effective July 17, 2025Exagen Inc.'s board of directors on July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee pursuant to the bylaws of the Company, appointed, effective as of July 17, 2025, Charles S. McKhann to serve as a Class III director, with an initial term expiring at the Company’s 2028 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Compensation Committee of the Board and the Nominating Committee. Also in connection with his appointment, the size of the Board was increased from seven (7) members to eight (8) members, effective as of the Effective Date. Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical Inc., a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery Inc., a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University.お知らせ • Jul 16Exagen Inc. to Report Q2, 2025 Results on Jul 29, 2025Exagen Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 29, 2025お知らせ • Jun 23Exagen Inc. Appoints Michael Mahler as Chief Scientific OfficerExagen Inc. announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases. His expertise will support Exagen's development of cutting-edge tools to improve patient outcomes.分析記事 • May 18Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The IndustryExagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...分析記事 • May 09Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...お知らせ • May 09Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million.Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000 Price\Range: $5.25 Discount Per Security: $0.315お知らせ • May 08Exagen Inc. has filed a Follow-on Equity Offering.Exagen Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • May 06Exagen Inc. Provides Earnings Guidance for Full Year 2025Exagen Inc. provided earnings guidance for full year 2025. For the full-year, the company expects revenue of at least $65 million.お知らせ • May 01Exagen Inc., Annual General Meeting, Jun 10, 2025Exagen Inc., Annual General Meeting, Jun 10, 2025. Location: exagen administrative offices, training room, 2175 salk avenue, 3rd floor,california 92008., carlsbad United StatesSeeking Alpha • Apr 26Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To ProfitabilitySummary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alphaお知らせ • Apr 22Exagen Inc. to Report Q1, 2025 Results on May 05, 2025Exagen Inc. announced that they will report Q1, 2025 results Pre-Market on May 05, 2025新しいナラティブ • Apr 09Biomarker Launch And AVISE CTD Expansion Will Drive Future Success New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth. 分析記事 • Apr 03There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price RiseThe Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...お知らせ • Mar 12Exagen Inc. Provides Earnings Guidance for First Quarter of 2025Exagen Inc. provides earnings guidance for first quarter of 2025. For the period, the company expects total revenue of at least $14.5 million. The company expects to provide its full-year 2025 financial outlook in connection with the release of its first quarter 2025 financial results.分析記事 • Mar 04Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Feb 26Exagen Inc. to Report Q4, 2024 Results on Mar 11, 2025Exagen Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 11, 2025分析記事 • Feb 05Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For ExcitementExagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...お知らせ • Jan 13Exagen Inc. Secures Conditional Ny State Approval for New Lupus and Rheumatoid Arthritis BiomarkersExagen Inc. announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays, with a planned commercial launch in January 2025. New AVISE CTD Biomarkers, The company’s new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expects these new biomarkers will further improve the clinical utility of AVISE CTD, and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. The new biomarkers are as follows: T-Cell Lupus profile comprises new biomarkers; TC4d, TIgG, and TIgM. These markers provide superior sensitivity for SLE compared to conventional SLE biomarkers, further enhancing their AVISE Lupus profile for a more comprehensive diagnosis, particularly in clinically ambiguous cases. RA profile includes additional anti-RA33 biomarkers; IgA, IgG, and IgM. These markers provide clinicians with more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis.分析記事 • Dec 22Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift TooDespite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...お知らせ • Nov 15Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformExagen Inc. announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue disease (CTD). A lack of diagnostic clarity may lead to serial and repeat testing, increased morbidity, worsening mortality rates and growing healthcare costs. The seven new biomarkers for AVISE CTD are as follows: A new T Cell Lupus profile will include three new T Cell biomarkers (TC4d, TIgG, TIgM). These provide enhanced sensitivity for SLE as compared to conventional SLE biomarkers and serve as a complement to the AVISE Lupus profile also included in the test. · The RA profile will be enhanced with the addition of four biomarkers (anti-CarP and anti-RA33 biomarkers IgA, IgG, IgM). Providers are given more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis. The AVISE CTD test that rheumatologists have come to know and trust is composed of multiple biomarker assays that assist in the clinical diagnosis of the most common CTDs, which included: SLE; RA; Sjögren's Disease; Mixed Connective Tissue Disease (MCTD); Antiphospholipid Syndrome; Myositis; Systemic Sclerosis; Graves’ Disease; Hashimoto’s Thyroiditis. Availability of the AVISE CTD test enhancements are pending conditional approval by the New York State Department of Health. Learn more about AVISE CTD [2] and its ability to provide unique diagnostic clarity.お知らせ • Nov 13Exagen Inc. Provides Earnings Guidance for the Full Year 2024Exagen Inc. provided earnings guidance for the full year 2024. The company now expected 2024 full-year revenue of $55 million to $56 million, primarily reflecting the impact of one-time adjustments in the third quarter.お知らせ • Oct 30Exagen Inc. to Report Q3, 2024 Results on Nov 12, 2024Exagen Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024分析記事 • Sep 06Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks JustifiedDespite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...分析記事 • Aug 07Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter ReportExagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...お知らせ • Aug 06Exagen Inc. Revises Earnings Guidance for the Full Year 2024Exagen Inc. revised earnings guidance for the full year 2024. Given continued improved performance, the company increasing guidance for full-year 2024 revenue to at least $57 million.お知らせ • Aug 03Exagen Inc. Announces Chief Financial Officer ChangesExagen Inc. announced the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. Mr. Black brings to Exagen more than 30 years of financial and accounting experience, having served in finance leadership roles for eight publicly traded companies. He currently serves as CFO of Standard BioTools, where he recently played a key leadership role in executing its merger with SomaLogic, creating a diversified leader in life science tools. Prior to that, he was CFO of Apollo Endosurgery, where he was instrumental in the Company turnaround and eventual $650 million sale to Boston Scientific. Previously, he spent over four years as CFO of Alphatec Spine, where he successfully closed nearly $500M in financing transactions to support accelerated growth, two strategic acquisitions and expansion of the company market cap from $20M to over $1B during his tenure. Previously to this role, Mr. Black served as Senior Vice President and Chief Financial Officer of Apollo Endosurgery Inc., a publicly traded, medical technology company focused on endoscopic therapies for gastrointestinal conditions and interventional treatment of obesity, from August 2021 until April 2023, when Apollo was acquired by Boston Scientific. Prior to joining Apollo, he served as Executive Vice President and Chief Financial Officer of Alphatec Holdings Inc., a publicly traded, medical technology company focused on the surgical treatment of spinal disorders, from March 2017 to April 2021. Prior to joining Alphatec, Mr. Black was Senior Vice President and Chief Financial Officer of Applied Proteomics Inc., a proteomics-based diagnostics company, Senior Vice President and Chief Financial Officer of AltheaDx Inc., a pharmacogenetics diagnostics company, and Senior Vice President and Chief Financial Officer of Verenium Corporation, an industrial biotechnology company. Mr. Black began his career at Ernst & Young LLP. Mr. Black is a member of the board of directors of Cellana Inc., a privately held company and developer of algae-based bioproducts, where he serves as chairperson of the audit committee. Mr. Black received his B.S. in Business from the University of Arizona.お知らせ • Jul 22Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024Exagen Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2024分析記事 • Jul 13Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...分析記事 • May 21Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Major Estimate Revision • May 20Consensus estimates of losses per share improve by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$54.2m to US$55.2m. EPS estimate increased from -US$1.36 per share to -US$1.18 per share. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 15% to US$1.88 over the past week.Recent Insider Transactions • May 19CEO, President & Director recently bought US$78k worth of stockOn the 16th of May, John Aballi bought around 40k shares on-market at roughly US$1.92 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of US$19k worth in shares.お知らせ • May 15Exagen Inc. Updates Earnings Guidance for the Full Year 2024Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.Reported Earnings • May 14First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.19 loss per share (improved from US$0.44 loss in 1Q 2023). Revenue: US$14.4m (up 28% from 1Q 2023). Net loss: US$3.36m (loss narrowed 56% from 1Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.お知らせ • May 01Exagen Inc. to Report Q1, 2024 Results on May 13, 2024Exagen Inc. announced that they will report Q1, 2024 results at 9:30 AM, US Eastern Standard Time on May 13, 2024お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 10, 2024Exagen Inc., Annual General Meeting, Jun 10, 2024, at 06:00 Pacific Standard Time. Location: Exagen Administrative Offices, Training Room, 2175 Salk Avenue, 3rd Floor, Carlsbad California United States Agenda: To elect three directors to serve as Class II directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; to ratify the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.お知らせ • Apr 27Exagen Inc. Announces Changes in Board of DirectorsExagen Inc. announced changes to the Board of Directors. Exagen announced Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief Science Officer. He then joined Illumina as its first Chief Information Officer and spent 12 years with the sequencing leader. He was most recently with LunaPBC as the Chief Information and Privacy Officer. Dr. Kahn currently holds Board positions at Blue Circle Health, Rady Children’s Institute for Genomic Medicine and Rady Children's Hospital. Dr. Kahn received a B.S. in Chemistry from Rider College, a Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine and was a Fellow Commoner at Churchill College and Postdoctoral Fellow at the University of Cambridge, England. Additionally, in an ever-continuing effort to streamline operations at the company, Exagen announced that it is reducing the size of the Board of Directors from nine to seven, a change that has been carefully planned and complements the long-term strategy. Brian Birk, Ebetuel Pallares, Ph.D. and Wendy Johnson have all agreed to step down from the Board of Directors, effective on the date of the annual shareholder meeting on June 10th, 2024.分析記事 • Mar 26Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price PlungeExagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Mar 22Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual ReportExagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...Reported Earnings • Mar 20Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$1.34 loss per share (improved from US$2.77 loss in FY 2022). Revenue: US$52.5m (up 15% from FY 2022). Net loss: US$23.7m (loss narrowed 50% from FY 2022). Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 08Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024Exagen Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 18, 2024お知らせ • Jan 08Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.New Risk • Dec 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$30m). Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$59k sold). Market cap is less than US$100m (US$25.9m market cap).Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.31 loss per share (improved from US$0.47 loss in 3Q 2022). Revenue: US$13.4m (down 8.9% from 3Q 2022). Net loss: US$5.42m (loss narrowed 33% from 3Q 2022). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • Nov 16Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$46.8m to US$50.4m. EPS estimate increased from -US$1.66 per share to -US$1.48 per share. Biotechs industry in the US expected to see average net income growth of 5.7% next year. Consensus price target of US$5.75 unchanged from last update. Share price rose 3.0% to US$1.54 over the past week.お知らせ • Oct 31Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023Exagen Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023Price Target Changed • Oct 25Price target decreased by 8.0% to US$5.75Down from US$6.25, the current price target is an average from 4 analysts. New target price is 262% above last closing price of US$1.59. Stock is down 34% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$2.77 last year.Recent Insider Transactions • Oct 20CEO, President & Director recently sold US$59k worth of stockOn the 17th of October, John Aballi sold around 34k shares on-market at roughly US$1.75 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, John has been a net buyer over the last 12 months, purchasing a net total of US$182k worth of shares.New Risk • Aug 07New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$37m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$37m). Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (US$42.2m market cap).Reported Earnings • Aug 07Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.28 loss per share (improved from US$0.86 loss in 2Q 2022). Revenue: US$14.1m (up 86% from 2Q 2022). Net loss: US$5.01m (loss narrowed 66% from 2Q 2022). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 26Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023Exagen Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 07, 2023お知らせ • Jul 25Exagen Inc. Appoints Paul Kim as Class II DirectorOn July 24, 2023, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the board) of Exagen Inc., and pursuant to the bylaws of the Company, the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board. In connection with his appointment to the Board, Mr. Kim was also appointed to the Audit Committee of the Board (the “Audit Committee) and the Compensation Committee of the Board (the Compensation Committee), effective as of July 24, 2023. Following Mr. Kim’s appointment, the Audit Committee consists of Frank Stokes (Chair), Wendy Johnson, Ana Hooker and Paul Kim, and the Compensation Committee consists of Bruce C. Robertson, Ph.D. (Chair), Ana Hooker and Paul Kim. Paul Kim has served as Fulgent Genetic Inc.’s (Fulgent) Chief Financial Officer since January 2016. Prior to his service for Fulgent, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent Inc., a publicly traded biometric identification services and product company, from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From April 1996 to January 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.分析記事 • Jul 21Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The IndustryWith a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...Reported Earnings • May 16First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.44 loss per share (improved from US$0.60 loss in 1Q 2022). Revenue: US$11.2m (up 8.0% from 1Q 2022). Net loss: US$7.69m (loss narrowed 25% from 1Q 2022). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Major Estimate Revision • Mar 27Consensus EPS estimates upgraded to US$1.92 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$49.3m to US$44.9m. 2023 losses expected to reduce from -US$2.19 to -US$1.92 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target down from US$6.50 to US$6.25. Share price was steady at US$2.23 over the past week.Reported Earnings • Mar 21Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: US$2.77 loss per share (further deteriorated from US$1.68 loss in FY 2021). Revenue: US$45.6m (down 5.7% from FY 2021). Net loss: US$47.4m (loss widened 77% from FY 2021). Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) missed analyst estimates by 2.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 14Price target decreased by 38% to US$6.50Down from US$10.50, the current price target is an average from 4 analysts. New target price is 154% above last closing price of US$2.56. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$2.70 next year compared to a net loss per share of US$1.68 last year.お知らせ • Jan 24Exagen Inc. Announces Board ChangesExagen Inc. announced that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.Dr. Nova currently serves as President of Veracyte's U.S. CLIA business where she leads all aspects of the company's broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million. She has held numerous leadership roles in the life science industry, which include CEO of Molecular Stethoscope and SVP & General Manager of Oncology at Illumina. Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011. She has also held senior positions with Nanogen Inc., Ligand Pharmaceuticals Inc. and Hybritech. Dr. Nova currently serves on the Board of Azenta and previously served on the Board of Directors of Veracyte and Arena Pharmaceuticals. Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside and a B.S. in Biological Sciences from the University of California, Irvine.Seeking Alpha • Oct 17Exagen appoints John Aballi as CEOExagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.Price Target Changed • Aug 26Price target decreased to US$12.25Down from US$14.50, the current price target is an average from 6 analysts. New target price is 170% above last closing price of US$4.54. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$2.89 next year compared to a net loss per share of US$1.68 last year.Major Estimate Revision • Aug 11Consensus revenue estimates fall by 19%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$53.4m to US$43.4m. Forecast losses increased from -US$2.08 to -US$2.87 per share. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target down from US$16.40 to US$14.50. Share price fell 34% to US$5.28 over the past week.分析記事 • Aug 10Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS NumbersMarket forces rained on the parade of Exagen Inc. ( NASDAQ:XGN ) shareholders today, when the analysts downgraded their...Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.78 loss per share (down from US$0.38 loss in 2Q 2021). Revenue: US$8.96m (down 30% from 2Q 2021). Net loss: US$13.3m (loss widened 108% from 2Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) also missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 35%, compared to a 46% growth forecast for the industry in the US.分析記事 • Jul 26Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Price Target Changed • May 14Price target decreased to US$16.40Down from US$18.00, the current price target is an average from 6 analysts. New target price is 240% above last closing price of US$4.83. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$2.06 next year compared to a net loss per share of US$1.68 last year.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.60 loss per share (down from US$0.48 loss in 1Q 2021). Revenue: US$10.4m (down 1.8% from 1Q 2021). Net loss: US$10.3m (loss widened 65% from 1Q 2021). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 17%, compared to a 25% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target decreased to US$18.00Down from US$24.20, the current price target is an average from 6 analysts. New target price is 200% above last closing price of US$6.00. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$2.04 next year compared to a net loss per share of US$1.68 last year.分析記事 • Apr 05Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Mar 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.8m to US$51.9m. Losses expected to increase from US$1.82 per share to US$2.04. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$24.20 to US$18.00. Share price rose 2.6% to US$8.40 over the past week.Price Target Changed • Mar 23Price target decreased to US$21.00Down from US$24.40, the current price target is an average from 6 analysts. New target price is 151% above last closing price of US$8.38. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$1.74 next year compared to a net loss per share of US$1.32 last year.分析記事 • Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$12.3m (up 14% from 3Q 2020). Net loss: US$7.18m (loss widened 67% from 3Q 2020).業績と収益の成長予測NasdaqGM:XGN - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202890-12-3N/A212/31/202779-12-7N/A712/31/202672-17-14N/A73/31/202668-20N/AN/AN/A12/31/202567-20-14-14N/A9/30/202564-19-11-10N/A6/30/202559-17-16-15N/A3/31/202557-16-15-15N/A12/31/202456-15-14-13N/A9/30/202456-17-6-5N/A6/30/202457-17-6-6N/A3/31/202456-19-14-14N/A12/31/202353-24-15-14N/A9/30/202352-32-30-29N/A6/30/202353-35-34-32N/A3/31/202346-45-37-33N/A12/31/202246-47-36-32N/A9/30/202245-40-37-32N/A6/30/202243-39-36-31N/A3/31/202248-31-28-25N/A12/31/202148-27-23-20N/A9/30/202148-23-19-18N/A6/30/202147-20-16-15N/A3/31/202143-17-16-15N/A12/31/202042-17-15-14N/A9/30/202040-17-15-14N/A6/30/202039-29-14-14N/A3/31/202041-31-11-11N/A12/31/201940-30N/A-10N/A9/30/201940-31N/A-8N/A6/30/201938-18N/A-8N/A3/31/201935-18N/A-8N/A12/31/201832-18N/A-9N/A12/31/201727-33N/A-11N/A12/31/201518-21N/A-12N/A9/30/201518-21N/A-11N/A6/30/201517-23N/A-10N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: XGN今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: XGN今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: XGN今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: XGNの収益 ( 9.7% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: XGNの収益 ( 9.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: XGNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/15 14:38終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Exagen Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Anderson SchockB. Riley Securities, Inc.Mark MassaroBTIGKyle MiksonCanaccord Genuity4 その他のアナリストを表示
分析記事 • May 14Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesExagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...
お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.
お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.
お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.
分析記事 • Nov 07Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...
お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.
分析記事 • May 14Exagen Inc. (NASDAQ:XGN) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesExagen Inc. ( NASDAQ:XGN ) just released its first-quarter report and things are looking bullish. Revenues and losses...
お知らせ • May 11Exagen Inc. Reaffirms Earnings Guidance for the full year 2026Exagen Inc. reaffirmed earnings guidance for the full year 2026. The company continues to expect full-year 2026 revenue of $70 million to $73 million.
お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 09, 2026Exagen Inc., Annual General Meeting, Jun 09, 2026. Location: training room, 2175 salk avenue, 3rd floor, carlsbad, california 92008, United States
お知らせ • Apr 27Exagen Inc. to Report Q1, 2026 Results on May 11, 2026Exagen Inc. announced that they will report Q1, 2026 results Pre-Market on May 11, 2026
ナラティブの更新 • Apr 24XGN: Volume Strength And 2026 Guidance Should Support Future Share GainsNarrative Update on Exagen Analysts have trimmed the average price target on Exagen by about $0.83 to reflect updated assumptions for slower revenue growth, softer profit margins, and more modest ASP and gross margin expansion in their models. Analyst Commentary Recent research shows analysts aligning around a more conservative view on Exagen, with several price targets reset to a tighter range as models are updated for softer pricing and margin assumptions.
ナラティブの更新 • Apr 10XGN: Shares Should Rise As Volumes Offset Transitory Pricing HeadwindsAnalysts have reduced their average 12 month price target on Exagen by a few dollars to around $9.50, citing lower than expected average selling prices as well as more conservative revenue and margin assumptions across recent research updates. Analyst Commentary Recent research updates point to a more cautious stance on Exagen, with several firms trimming their price targets while maintaining generally positive ratings on the shares.
ナラティブの更新 • Mar 26XGN: Shares Should Rise As Volumes Support Long Term Margin RecoveryAnalysts have reset expectations on Exagen, with several firms trimming their price targets to around $9 to $10. They cite lower than anticipated average selling prices, tempered revenue growth assumptions, and more gradual gross margin expansion in their updated models.
ナラティブの更新 • Mar 12XGN: Shares Should Rise As Solid Volumes Offset Near Term Pricing HeadwindsThe analyst price target for Exagen has been revised from a fair value of $13.29 to $9.50. Analysts have updated their models to account for lower near-term average selling prices, more conservative revenue growth assumptions, and more modest margin expectations, although overall volume trends remain generally stable.
お知らせ • Mar 10Exagen Inc. Provides Earnings Guidance for Full Year 2026Exagen Inc. provided earnings guidance for full year 2026. For the year, the company expects revenue of $70 million to $73 million.
お知らせ • Feb 24Exagen Inc. to Report Q4, 2025 Results on Mar 10, 2026Exagen Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 10, 2026
ナラティブの更新 • Feb 11XGN: Shares Will Rise As 2025 Revenue Guidance Supports Bullish OutlookNarrative Update on Exagen The updated analyst price target for Exagen has moved lower to about $13.29 from $14.71. This reflects analysts' recent cuts to formal targets in the diagnostics group and slightly more conservative assumptions on fair value, discount rate, revenue growth, profit margin and future P/E.
ナラティブの更新 • Jan 27XGN: Shares Will Rise As 2025 Guidance And Sector Fundamentals Strengthen OutlookAnalysts trimmed their price target on Exagen to $13 from $18, citing updated sector views from recent Q4 previews, even as they continue to expect solid diagnostics group fundamentals and 2026 outlooks. Analyst Commentary Bullish Takeaways Bullish analysts view the updated US$13 price target as still supported by what they describe as solid fundamentals across the diagnostics group, which they see as relevant for Exagen's valuation framework.
分析記事 • Jan 14Investors Don't See Light At End Of Exagen Inc.'s (NASDAQ:XGN) Tunnel And Push Stock Down 28%Unfortunately for some shareholders, the Exagen Inc. ( NASDAQ:XGN ) share price has dived 28% in the last thirty days...
ナラティブの更新 • Jan 12XGN: Shares Will Rise As 2025 Guidance Supports Profitability MilestoneThe updated analyst price target for Exagen reflects a move to roughly $14.71 from about $15.43, as analysts weigh mixed signals from recent target changes and sector commentary around solid diagnostics fundamentals, alongside ongoing headwinds in life science tools. Analyst Commentary Recent research on Exagen points to a mixed but constructive view, with price targets adjusted both higher and lower as analysts rework their models around upcoming earnings and sector trends.
お知らせ • Jan 12Exagen Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2025Exagen Inc. provided earnings guidance for the fourth quarter and full year ended December 31, 2025. For the quarter, the company expects Total Revenue to be $16 million to $17 million. For the year, the company expects Total Revenue to be $66 million to $67 million. Record full year 2025 revenue, an increase of at least 19% over 2024.
ナラティブの更新 • Dec 21XGN: Shares Will Rise As Resilient Demand Supports 2025 Profitability ProspectsAnalysts raised their price target on Exagen to $15.00 from $11.00, citing updated models ahead of Q3 results that account for resilient fundamentals despite ongoing headwinds in life science tools, including tariffs, funding uncertainty, and China related pressures. Analyst Commentary Bullish analysts view the higher price target as a reflection of Exagen's ability to execute against a difficult macro backdrop and to sustain growth despite sector wide pressures.
分析記事 • Dec 18Is Exagen (NASDAQ:XGN) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
ナラティブの更新 • Dec 07XGN: Shares Will Rise As Autoimmune Test Adoption Drives 50% Upside PotentialAnalysts have lifted their price target on Exagen to $15 from $11, citing a refreshed model that reflects confidence in the company’s autoimmune diagnostics platform and its flagship AVISE CTD test, despite ongoing macro headwinds in the life science tools sector. Analyst Commentary Bullish analysts point to Exagen’s specialized focus on autoimmune diagnostics and its AVISE CTD test as key drivers of potential upside, supporting the higher price target and Buy rating in spite of sector-wide pressures.
ナラティブの更新 • Nov 22XGN: Shares Will Gain As Buy Ratings Signal 50% Upside PotentialAnalysts have raised their price target for Exagen from $14.00 to $15.43. They cite improved revenue growth estimates and ongoing optimism for the company's diagnostic test portfolio, despite sector headwinds.
分析記事 • Nov 18The Market Doesn't Like What It Sees From Exagen Inc.'s (NASDAQ:XGN) Revenues Yet As Shares Tumble 27%Exagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...
分析記事 • Nov 07Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43It's been a sad week for Exagen Inc. ( NASDAQ:XGN ), who've watched their investment drop 12% to US$10.38 in the week...
ナラティブの更新 • Nov 06XGN: Shares Set To Climb On Strong Buy Ratings And 50% Upside PotentialAnalysts have raised their price target for Exagen, increasing it from approximately $13.14 to $14.00 per share. They cite improved profit margin forecasts and confidence in the company’s diagnostic offerings, despite ongoing sector challenges.
お知らせ • Nov 05Exagen Inc. Reiterates Earnings Guidance for the Year 2025Exagen Inc. reiterated earnings guidance for the year 2025. For the year, the company expects revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to achieve positive adjusted EBITDA in the fourth quarter of 2025.
ナラティブの更新 • Oct 23Analysts Boost Exagen Price Target Highlighting Growth Potential and Strong Diagnostic PortfolioAnalysts have raised their price target for Exagen from approximately $11.17 to $13.14. They cite confidence in the company’s diagnostic test portfolio and expectations for improved adoption and financial performance.
お知らせ • Oct 22Exagen Inc. to Report Q3, 2025 Results on Nov 04, 2025Exagen Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 04, 2025
Seeking Alpha • Sep 13Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For NowSummary Exagen Inc. has rebounded to 52-week highs, driven by record Q2 revenue, higher ASP, and a strengthened balance sheet. XGN's pipeline, including PAD4 and lupus nephritis diagnostics, presents significant long-term growth opportunities but faces regulatory and reimbursement risks. Recent payer wins and executive appointments enhance commercial prospects, but collections risk and delayed insurance payments threaten near-term revenue stability. Given execution risks and valuation premium, I rate XGN as HOLD, awaiting clearer visibility on collections, payer wins, and PAD4 approval. Read the full article on Seeking Alpha
分析記事 • Aug 05Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift TooNasdaqGM:XGN 1 Year Share Price vs Fair Value Explore Exagen's Fair Values from the Community and select yours Despite...
分析記事 • Aug 01Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent ResultsIt's been a pretty great week for Exagen Inc. ( NASDAQ:XGN ) shareholders, with its shares surging 16% to US$8.40 in...
お知らせ • Jul 29Exagen Inc. Provides Earnings Guidance for the Full Year 2025Exagen Inc. provided earnings guidance for the full year 2025. For the year, company expects 2025 full-year revenue of between $65 million and $70 million, and at the high end of the revenue range would expect to hit positive adjusted EBITDA in the fourth quarter.
お知らせ • Jul 18Exagen Inc. Appoints Charles S. McKhann as A Class III Director and to the Compensation Committee and Nominating Committee, Effective July 17, 2025Exagen Inc.'s board of directors on July 17, 2025, upon the recommendation of the Nominating and Corporate Governance Committee pursuant to the bylaws of the Company, appointed, effective as of July 17, 2025, Charles S. McKhann to serve as a Class III director, with an initial term expiring at the Company’s 2028 annual meeting of stockholders. In connection with and effective as of his appointment to the Board, Mr. McKhann was also appointed to the Compensation Committee of the Board and the Nominating Committee. Also in connection with his appointment, the size of the Board was increased from seven (7) members to eight (8) members, effective as of the Effective Date. Mr. McKhann served as the President, Chief Executive Officer, and a member of the board of directors of Silk Road Medical Inc., a medical device company, from November 2023 to September 2024, when Silk Road was purchased by Boston Scientific Corporation, and served as Chief Executive Officer, President and a member of the Board of Directors of Apollo Endosurgery Inc., a medical device company, from March 2021 to April 4, 2023, when Apollo was purchased by Boston Scientific. From October 2017 to December 2018, Mr. McKhann served as Chief Commercial Officer at ROX Medical Inc., a medical device company. From July 2016 to April 2017, he served as Chief Commercial Officer of Torax Medical Inc., a medical device company acquired by Johnson & Johnson in April 2017. From January 2015 to July 2016, he served as Chief Commercial Officer of Intersect ENT Inc., a medical device company. In addition, from September 2012 to March 2021, he served as Managing Director of Vernon Consulting Inc. Mr. McKhann holds a B.A. in Political Sciences and Economics and an M.B.A. from Stanford University.
お知らせ • Jul 16Exagen Inc. to Report Q2, 2025 Results on Jul 29, 2025Exagen Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 29, 2025
お知らせ • Jun 23Exagen Inc. Appoints Michael Mahler as Chief Scientific OfficerExagen Inc. announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune research. At the same time, Dr. Mahler initiated a productive and lasting collaboration with one of his mentors, Dr. Marvin J. Fritzler, a thought leader in the field whose research spans a wide range of topics, including autoimmune disease, the biology of autoantigens, and novel diagnostic technologies. Over the course of his distinguished career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. His transformative work has led to the discovery of several novel autoantigens and the development of innovative diagnostic solutions. His scientific contributions have resulted in over 300 peer-reviewed publications and numerous patents, advancing the accurate diagnosis of autoimmune diseases. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases. His expertise will support Exagen's development of cutting-edge tools to improve patient outcomes.
分析記事 • May 18Exagen Inc.'s (NASDAQ:XGN) Shares Bounce 34% But Its Business Still Trails The IndustryExagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 34% gain in the last month alone. The...
分析記事 • May 09Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$7.75As you might know, Exagen Inc. ( NASDAQ:XGN ) recently reported its quarterly numbers. It looks like a positive result...
お知らせ • May 09Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million.Exagen Inc. has completed a Follow-on Equity Offering in the amount of $17.5875 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000 Price\Range: $5.25 Discount Per Security: $0.315
お知らせ • May 08Exagen Inc. has filed a Follow-on Equity Offering.Exagen Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • May 06Exagen Inc. Provides Earnings Guidance for Full Year 2025Exagen Inc. provided earnings guidance for full year 2025. For the full-year, the company expects revenue of at least $65 million.
お知らせ • May 01Exagen Inc., Annual General Meeting, Jun 10, 2025Exagen Inc., Annual General Meeting, Jun 10, 2025. Location: exagen administrative offices, training room, 2175 salk avenue, 3rd floor,california 92008., carlsbad United States
Seeking Alpha • Apr 26Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To ProfitabilitySummary We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches. Key risks include reimbursement uncertainty, competition, cash burn, and execution challenges, but these are balanced by the stock's current valuation and growth potential. Read the full article on Seeking Alpha
お知らせ • Apr 22Exagen Inc. to Report Q1, 2025 Results on May 05, 2025Exagen Inc. announced that they will report Q1, 2025 results Pre-Market on May 05, 2025
新しいナラティブ • Apr 09Biomarker Launch And AVISE CTD Expansion Will Drive Future Success New biomarkers and biopharma partnerships are expected to drive revenue growth and enhance diagnostic capabilities, accelerating earnings growth.
分析記事 • Apr 03There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 45% Share Price RiseThe Exagen Inc. ( NASDAQ:XGN ) share price has done very well over the last month, posting an excellent gain of 45...
お知らせ • Mar 12Exagen Inc. Provides Earnings Guidance for First Quarter of 2025Exagen Inc. provides earnings guidance for first quarter of 2025. For the period, the company expects total revenue of at least $14.5 million. The company expects to provide its full-year 2025 financial outlook in connection with the release of its first quarter 2025 financial results.
分析記事 • Mar 04Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Feb 26Exagen Inc. to Report Q4, 2024 Results on Mar 11, 2025Exagen Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 11, 2025
分析記事 • Feb 05Exagen Inc. (NASDAQ:XGN) Surges 40% Yet Its Low P/S Is No Reason For ExcitementExagen Inc. ( NASDAQ:XGN ) shares have continued their recent momentum with a 40% gain in the last month alone. The...
お知らせ • Jan 13Exagen Inc. Secures Conditional Ny State Approval for New Lupus and Rheumatoid Arthritis BiomarkersExagen Inc. announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays, with a planned commercial launch in January 2025. New AVISE CTD Biomarkers, The company’s new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expects these new biomarkers will further improve the clinical utility of AVISE CTD, and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. The new biomarkers are as follows: T-Cell Lupus profile comprises new biomarkers; TC4d, TIgG, and TIgM. These markers provide superior sensitivity for SLE compared to conventional SLE biomarkers, further enhancing their AVISE Lupus profile for a more comprehensive diagnosis, particularly in clinically ambiguous cases. RA profile includes additional anti-RA33 biomarkers; IgA, IgG, and IgM. These markers provide clinicians with more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis.
分析記事 • Dec 22Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift TooDespite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 26% in the last...
お知らせ • Nov 15Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD PlatformExagen Inc. announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis of a connective tissue disease (CTD). A lack of diagnostic clarity may lead to serial and repeat testing, increased morbidity, worsening mortality rates and growing healthcare costs. The seven new biomarkers for AVISE CTD are as follows: A new T Cell Lupus profile will include three new T Cell biomarkers (TC4d, TIgG, TIgM). These provide enhanced sensitivity for SLE as compared to conventional SLE biomarkers and serve as a complement to the AVISE Lupus profile also included in the test. · The RA profile will be enhanced with the addition of four biomarkers (anti-CarP and anti-RA33 biomarkers IgA, IgG, IgM). Providers are given more data to confidently identify patients with RA and substantiate a seronegative RA diagnosis. The AVISE CTD test that rheumatologists have come to know and trust is composed of multiple biomarker assays that assist in the clinical diagnosis of the most common CTDs, which included: SLE; RA; Sjögren's Disease; Mixed Connective Tissue Disease (MCTD); Antiphospholipid Syndrome; Myositis; Systemic Sclerosis; Graves’ Disease; Hashimoto’s Thyroiditis. Availability of the AVISE CTD test enhancements are pending conditional approval by the New York State Department of Health. Learn more about AVISE CTD [2] and its ability to provide unique diagnostic clarity.
お知らせ • Nov 13Exagen Inc. Provides Earnings Guidance for the Full Year 2024Exagen Inc. provided earnings guidance for the full year 2024. The company now expected 2024 full-year revenue of $55 million to $56 million, primarily reflecting the impact of one-time adjustments in the third quarter.
お知らせ • Oct 30Exagen Inc. to Report Q3, 2024 Results on Nov 12, 2024Exagen Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 12, 2024
分析記事 • Sep 06Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks JustifiedDespite an already strong run, Exagen Inc. ( NASDAQ:XGN ) shares have been powering on, with a gain of 40% in the last...
分析記事 • Aug 07Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter ReportExagen Inc. ( NASDAQ:XGN ) just released its quarterly report and things are looking bullish. The results overall were...
お知らせ • Aug 06Exagen Inc. Revises Earnings Guidance for the Full Year 2024Exagen Inc. revised earnings guidance for the full year 2024. Given continued improved performance, the company increasing guidance for full-year 2024 revenue to at least $57 million.
お知らせ • Aug 03Exagen Inc. Announces Chief Financial Officer ChangesExagen Inc. announced the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. Mr. Black brings to Exagen more than 30 years of financial and accounting experience, having served in finance leadership roles for eight publicly traded companies. He currently serves as CFO of Standard BioTools, where he recently played a key leadership role in executing its merger with SomaLogic, creating a diversified leader in life science tools. Prior to that, he was CFO of Apollo Endosurgery, where he was instrumental in the Company turnaround and eventual $650 million sale to Boston Scientific. Previously, he spent over four years as CFO of Alphatec Spine, where he successfully closed nearly $500M in financing transactions to support accelerated growth, two strategic acquisitions and expansion of the company market cap from $20M to over $1B during his tenure. Previously to this role, Mr. Black served as Senior Vice President and Chief Financial Officer of Apollo Endosurgery Inc., a publicly traded, medical technology company focused on endoscopic therapies for gastrointestinal conditions and interventional treatment of obesity, from August 2021 until April 2023, when Apollo was acquired by Boston Scientific. Prior to joining Apollo, he served as Executive Vice President and Chief Financial Officer of Alphatec Holdings Inc., a publicly traded, medical technology company focused on the surgical treatment of spinal disorders, from March 2017 to April 2021. Prior to joining Alphatec, Mr. Black was Senior Vice President and Chief Financial Officer of Applied Proteomics Inc., a proteomics-based diagnostics company, Senior Vice President and Chief Financial Officer of AltheaDx Inc., a pharmacogenetics diagnostics company, and Senior Vice President and Chief Financial Officer of Verenium Corporation, an industrial biotechnology company. Mr. Black began his career at Ernst & Young LLP. Mr. Black is a member of the board of directors of Cellana Inc., a privately held company and developer of algae-based bioproducts, where he serves as chairperson of the audit committee. Mr. Black received his B.S. in Business from the University of Arizona.
お知らせ • Jul 22Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024Exagen Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 05, 2024
分析記事 • Jul 13Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share PriceYou may think that with a price-to-sales (or "P/S") ratio of 0.6x Exagen Inc. ( NASDAQ:XGN ) is definitely a stock...
分析記事 • May 21Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Major Estimate Revision • May 20Consensus estimates of losses per share improve by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from US$54.2m to US$55.2m. EPS estimate increased from -US$1.36 per share to -US$1.18 per share. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$5.50 unchanged from last update. Share price rose 15% to US$1.88 over the past week.
Recent Insider Transactions • May 19CEO, President & Director recently bought US$78k worth of stockOn the 16th of May, John Aballi bought around 40k shares on-market at roughly US$1.92 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. John has been a buyer over the last 12 months, purchasing a net total of US$19k worth in shares.
お知らせ • May 15Exagen Inc. Updates Earnings Guidance for the Full Year 2024Exagen Inc. updated earnings guidance for the full year 2024. For full year 2024 revenue, company is increasing guidance to at least $55 million.
Reported Earnings • May 14First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.19 loss per share (improved from US$0.44 loss in 1Q 2023). Revenue: US$14.4m (up 28% from 1Q 2023). Net loss: US$3.36m (loss narrowed 56% from 1Q 2023). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) also surpassed analyst estimates by 48%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
お知らせ • May 01Exagen Inc. to Report Q1, 2024 Results on May 13, 2024Exagen Inc. announced that they will report Q1, 2024 results at 9:30 AM, US Eastern Standard Time on May 13, 2024
お知らせ • Apr 28Exagen Inc., Annual General Meeting, Jun 10, 2024Exagen Inc., Annual General Meeting, Jun 10, 2024, at 06:00 Pacific Standard Time. Location: Exagen Administrative Offices, Training Room, 2175 Salk Avenue, 3rd Floor, Carlsbad California United States Agenda: To elect three directors to serve as Class II directors for a three-year term expiring at the 2027 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified; to ratify the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.
お知らせ • Apr 27Exagen Inc. Announces Changes in Board of DirectorsExagen Inc. announced changes to the Board of Directors. Exagen announced Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief Science Officer. He then joined Illumina as its first Chief Information Officer and spent 12 years with the sequencing leader. He was most recently with LunaPBC as the Chief Information and Privacy Officer. Dr. Kahn currently holds Board positions at Blue Circle Health, Rady Children’s Institute for Genomic Medicine and Rady Children's Hospital. Dr. Kahn received a B.S. in Chemistry from Rider College, a Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine and was a Fellow Commoner at Churchill College and Postdoctoral Fellow at the University of Cambridge, England. Additionally, in an ever-continuing effort to streamline operations at the company, Exagen announced that it is reducing the size of the Board of Directors from nine to seven, a change that has been carefully planned and complements the long-term strategy. Brian Birk, Ebetuel Pallares, Ph.D. and Wendy Johnson have all agreed to step down from the Board of Directors, effective on the date of the annual shareholder meeting on June 10th, 2024.
分析記事 • Mar 26Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price PlungeExagen Inc. ( NASDAQ:XGN ) shareholders won't be pleased to see that the share price has had a very rough month...
分析記事 • Mar 22Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual ReportExagen Inc. ( NASDAQ:XGN ) just released its latest yearly results and things are looking bullish. Exagen beat...
Reported Earnings • Mar 20Full year 2023 earnings: EPS and revenues exceed analyst expectationsFull year 2023 results: US$1.34 loss per share (improved from US$2.77 loss in FY 2022). Revenue: US$52.5m (up 15% from FY 2022). Net loss: US$23.7m (loss narrowed 50% from FY 2022). Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.1%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 08Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024Exagen Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 18, 2024
お知らせ • Jan 08Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023Exagen Inc. reaffirmed earnings guidance for the full year ended December 31, 2023. For the year, the company expected total revenue of at least $50 million.
New Risk • Dec 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$30m). Currently unprofitable and not forecast to become profitable over next 3 years (US$22m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (4.5% increase in shares outstanding). Significant insider selling over the past 3 months (US$59k sold). Market cap is less than US$100m (US$25.9m market cap).
Reported Earnings • Nov 17Third quarter 2023 earnings: EPS and revenues exceed analyst expectationsThird quarter 2023 results: US$0.31 loss per share (improved from US$0.47 loss in 3Q 2022). Revenue: US$13.4m (down 8.9% from 3Q 2022). Net loss: US$5.42m (loss narrowed 33% from 3Q 2022). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 33%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • Nov 16Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$46.8m to US$50.4m. EPS estimate increased from -US$1.66 per share to -US$1.48 per share. Biotechs industry in the US expected to see average net income growth of 5.7% next year. Consensus price target of US$5.75 unchanged from last update. Share price rose 3.0% to US$1.54 over the past week.
お知らせ • Oct 31Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023Exagen Inc. announced that they will report Q3, 2023 results After-Market on Nov 13, 2023
Price Target Changed • Oct 25Price target decreased by 8.0% to US$5.75Down from US$6.25, the current price target is an average from 4 analysts. New target price is 262% above last closing price of US$1.59. Stock is down 34% over the past year. The company is forecast to post a net loss per share of US$1.66 next year compared to a net loss per share of US$2.77 last year.
Recent Insider Transactions • Oct 20CEO, President & Director recently sold US$59k worth of stockOn the 17th of October, John Aballi sold around 34k shares on-market at roughly US$1.75 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, John has been a net buyer over the last 12 months, purchasing a net total of US$182k worth of shares.
New Risk • Aug 07New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$37m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$37m). Currently unprofitable and not forecast to become profitable over next 3 years (US$26m net loss in 3 years). Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Market cap is less than US$100m (US$42.2m market cap).
Reported Earnings • Aug 07Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.28 loss per share (improved from US$0.86 loss in 2Q 2022). Revenue: US$14.1m (up 86% from 2Q 2022). Net loss: US$5.01m (loss narrowed 66% from 2Q 2022). Revenue exceeded analyst estimates by 29%. Earnings per share (EPS) also surpassed analyst estimates by 43%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 26Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023Exagen Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 07, 2023
お知らせ • Jul 25Exagen Inc. Appoints Paul Kim as Class II DirectorOn July 24, 2023, upon recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the board) of Exagen Inc., and pursuant to the bylaws of the Company, the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board. In connection with his appointment to the Board, Mr. Kim was also appointed to the Audit Committee of the Board (the “Audit Committee) and the Compensation Committee of the Board (the Compensation Committee), effective as of July 24, 2023. Following Mr. Kim’s appointment, the Audit Committee consists of Frank Stokes (Chair), Wendy Johnson, Ana Hooker and Paul Kim, and the Compensation Committee consists of Bruce C. Robertson, Ph.D. (Chair), Ana Hooker and Paul Kim. Paul Kim has served as Fulgent Genetic Inc.’s (Fulgent) Chief Financial Officer since January 2016. Prior to his service for Fulgent, Mr. Kim was retired from 2011 until 2015 and served as Chief Financial Officer of Cogent Inc., a publicly traded biometric identification services and product company, from 2004 until 2011. Mr. Kim’s past experience also includes service as the Chief Financial Officer of JNI Corporation, a publicly traded storage area network technology company, from 2002 until 2003, as Vice President, Finance and Corporate Controller at JNI from October 1999 to August 2002 and as Vice President of Finance and Administration for Datafusion Inc., a privately held software development company, from 1998 until 1999. From April 1996 to January 1998, Mr. Kim was the Corporate Controller for Interlink Computer Sciences Inc., a publicly traded enterprise software company. From 1990 to 1996, Mr. Kim worked for Coopers and Lybrand L.L.P., leaving as an audit manager. Mr. Kim received a B.A. in Economics from the University of California at Berkeley in 1989 and is a Certified Public Accountant.
分析記事 • Jul 21Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The IndustryWith a price-to-sales (or "P/S") ratio of 0.9x Exagen Inc. ( NASDAQ:XGN ) may be sending very bullish signals at the...
Reported Earnings • May 16First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.44 loss per share (improved from US$0.60 loss in 1Q 2022). Revenue: US$11.2m (up 8.0% from 1Q 2022). Net loss: US$7.69m (loss narrowed 25% from 1Q 2022). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Mar 27Consensus EPS estimates upgraded to US$1.92 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$49.3m to US$44.9m. 2023 losses expected to reduce from -US$2.19 to -US$1.92 per share. Biotechs industry in the US expected to see average net income decline 50% next year. Consensus price target down from US$6.50 to US$6.25. Share price was steady at US$2.23 over the past week.
Reported Earnings • Mar 21Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: US$2.77 loss per share (further deteriorated from US$1.68 loss in FY 2021). Revenue: US$45.6m (down 5.7% from FY 2021). Net loss: US$47.4m (loss widened 77% from FY 2021). Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) missed analyst estimates by 2.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 14Price target decreased by 38% to US$6.50Down from US$10.50, the current price target is an average from 4 analysts. New target price is 154% above last closing price of US$2.56. Stock is down 70% over the past year. The company is forecast to post a net loss per share of US$2.70 next year compared to a net loss per share of US$1.68 last year.
お知らせ • Jan 24Exagen Inc. Announces Board ChangesExagen Inc. announced that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk, who has served as Chair of the Board of Directors at Exagen since 2018, and who will remain a member of the Board.Dr. Nova currently serves as President of Veracyte's U.S. CLIA business where she leads all aspects of the company's broad menu of diagnostic laboratory tests. She previously held the position of President & CEO of Decipher Biosciences until March 2021, when Veracyte purchased the organization for $600 million. She has held numerous leadership roles in the life science industry, which include CEO of Molecular Stethoscope and SVP & General Manager of Oncology at Illumina. Dr. Nova was the co-founder, President & CEO of Genoptix, which was purchased by Novartis AG for $470 million in 2011. She has also held senior positions with Nanogen Inc., Ligand Pharmaceuticals Inc. and Hybritech. Dr. Nova currently serves on the Board of Azenta and previously served on the Board of Directors of Veracyte and Arena Pharmaceuticals. Dr. Nova holds a Ph.D. in Biochemistry from the University of California, Riverside and a B.S. in Biological Sciences from the University of California, Irvine.
Seeking Alpha • Oct 17Exagen appoints John Aballi as CEOExagen (NASDAQ:XGN) has appointed John Aballi as CEO and President. Longtime CEO and President Ron Rocca, who took the company public and built a robust growth business, is stepping down after 11 years at the helm. Most recently, John Aballi served as SVP, General Manager, Urology & CLIA COO at Veracyte.
Price Target Changed • Aug 26Price target decreased to US$12.25Down from US$14.50, the current price target is an average from 6 analysts. New target price is 170% above last closing price of US$4.54. Stock is down 67% over the past year. The company is forecast to post a net loss per share of US$2.89 next year compared to a net loss per share of US$1.68 last year.
Major Estimate Revision • Aug 11Consensus revenue estimates fall by 19%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$53.4m to US$43.4m. Forecast losses increased from -US$2.08 to -US$2.87 per share. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target down from US$16.40 to US$14.50. Share price fell 34% to US$5.28 over the past week.
分析記事 • Aug 10Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS NumbersMarket forces rained on the parade of Exagen Inc. ( NASDAQ:XGN ) shareholders today, when the analysts downgraded their...
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.78 loss per share (down from US$0.38 loss in 2Q 2021). Revenue: US$8.96m (down 30% from 2Q 2021). Net loss: US$13.3m (loss widened 108% from 2Q 2021). Revenue missed analyst estimates by 26%. Earnings per share (EPS) also missed analyst estimates by 38%. Over the next year, revenue is forecast to grow 35%, compared to a 46% growth forecast for the industry in the US.
分析記事 • Jul 26Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Price Target Changed • May 14Price target decreased to US$16.40Down from US$18.00, the current price target is an average from 6 analysts. New target price is 240% above last closing price of US$4.83. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$2.06 next year compared to a net loss per share of US$1.68 last year.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: US$0.60 loss per share (down from US$0.48 loss in 1Q 2021). Revenue: US$10.4m (down 1.8% from 1Q 2021). Net loss: US$10.3m (loss widened 65% from 1Q 2021). Revenue exceeded analyst estimates by 3.9%. Earnings per share (EPS) also surpassed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 17%, compared to a 25% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target decreased to US$18.00Down from US$24.20, the current price target is an average from 6 analysts. New target price is 200% above last closing price of US$6.00. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$2.04 next year compared to a net loss per share of US$1.68 last year.
分析記事 • Apr 05Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Mar 29Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$55.8m to US$51.9m. Losses expected to increase from US$1.82 per share to US$2.04. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target down from US$24.20 to US$18.00. Share price rose 2.6% to US$8.40 over the past week.
Price Target Changed • Mar 23Price target decreased to US$21.00Down from US$24.40, the current price target is an average from 6 analysts. New target price is 151% above last closing price of US$8.38. Stock is down 50% over the past year. The company is forecast to post a net loss per share of US$1.74 next year compared to a net loss per share of US$1.32 last year.
分析記事 • Dec 03Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Nov 12Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$12.3m (up 14% from 3Q 2020). Net loss: US$7.18m (loss widened 67% from 3Q 2020).
